Coherus BioSciences (CHRS) FY Conference Transcript

Coherus BioSciences (CHRS) FY Conference Summary Company Overview - Coherus BioSciences has transitioned into an innovative oncology company, divesting its biosimilar assets, including Lucentis, Yosemir, and UDENYCA, generating approximately $800 million in total from these divestitures [3][4] - The company has paid off$480 million in long-term debt and added $250 million to its balance sheet [3] Key Developments Loktorzi - Loktorzi is a central asset in Coherus' strategy, with ongoing pivotal trials for additional indications [4][5] - The launch for nasopharyngeal carcinoma (NPC) showed good growth in Q4, but Q1 was flat due to supply interruptions and sales team distractions [10][11] - The focus is on increasing the breadth of physician prescriptions, depth of market penetration, and ensuring patient duration on the product [12][13] Partnerships and Clinical Studies - Coherus announced a partnership for combination studies with STC 15 from Storm Therapeutics, targeting RNA methyltransferase activity, which has shown promise in solid tumors [16][17] - The goal is to drive label expansion for Torapalumab, a next-generation PD-1 inhibitor, through these partnerships [20][21] CHS 1 114 (Treg Depleter) - CHS 1 114 targets CCR8 to selectively deplete tumor-resident Tregs, showing promising early clinical data with significant Treg depletion and CD8 T cell infiltration [23][25][26] - The combination with Torapalumab in late-line head and neck cancer patients has shown early signs of activity, with ongoing studies to evaluate its efficacy further [27][28] Casdozoketug - Casdozoketug is an IL-27 antagonist showing promising results in liver cancer, with a 17% complete response rate in early studies, which is significantly higher than reported rates in phase three studies [41][42] - The company is planning to progress with studies in both liver and lung cancers, with data expected next year [44][46] Financial and Strategic Outlook - Coherus is focused on execution and leveraging its strong track record in development, regulatory affairs, and commercial success [48][49] - The company anticipates promising results from ongoing clinical trials and partnerships, positioning itself for growth in the oncology market [8][49] Additional Insights - The company is actively exploring other tumor types for CHS 1 114, indicating a broadening of its clinical focus [29] - The strategic emphasis on enhancing the commercial story and execution capabilities is expected to drive future success [48][49]